The short answer
Medicare negotiated prices for ten Part D drugs, and those prices take effect on January 1, 2026. CMS publishes the list of drugs and their negotiated prices. What it has not published is a saving figure for any individual person.
Medicare can now negotiate what it pays for certain drugs directly with the companies that make them, and the first ten negotiated prices arrive this January. What has not arrived is any way to look up what that does to your own bill.
What is Medicare drug price negotiation?
The Inflation Reduction Act gave Medicare the ability to negotiate the prices of certain drugs directly with the companies that make them. Not every drug qualifies. The law aims at high expenditure, single source drugs that have no generic or biosimilar competition.
Those three conditions are doing the selecting, and they explain the shape of the list better than any individual name on it would.
High expenditure means Medicare is already spending a great deal on it. Single source means one company makes it. No generic or biosimilar competition means nothing cheaper exists to push the price down on its own.
Put together, the program targets drugs where the ordinary market pressure that lowers prices is absent. CMS selected ten Part D drugs for the first cycle.
The law has its own name for the result. A negotiated price is a Maximum Fair Price, and that phrase is worth holding on to, because a ceiling on a price is a different object from a discount on a bill.
Which drugs are on the list?
CMS publishes the list, with each drug and its negotiated price, in its own fact sheet on the Medicare Drug Price Negotiation Program. This publication does not reproduce it here. The reason is worth stating rather than hiding, because it is the same reason you can trust every other number on this page.
The list is published as a document rather than as text this publication could verify line by line on the page it was read from. Copying a list of drug names and prices from a summary, on a page about what your medicines cost, is exactly the kind of second hand specific this publication refuses to print.
So the honest instruction is to read it at the source. CMS's fact sheet on negotiated prices for 2026 carries the full list, and it is linked at the end of this article.
What can be said about the shape of it is published and useful. The ten selected drugs treat a range of conditions including cardiovascular disease, diabetes, autoimmune diseases and cancer.
They are also not a small corner of the program. Between January 1 and December 31, 2023, about 8.8 million of the 54 million people with Part D coverage were dispensed one of these drugs.
When do the new prices take effect?
January 1, 2026. That is the first date on which the negotiated prices apply to the ten selected Part D drugs, and CMS refers to it as the initial price applicability year. Before that date the program existed as a process. From that date it exists as a price a pharmacy can charge.
A negotiated price does not then sit still. For each year after the first, CMS publishes an updated price for each selected drug, equal to the previous year's price increased by the annual rise in the Consumer Price Index for all urban consumers.
It can also change if CMS and the manufacturer renegotiate.
The program is not finished either. CMS published draft guidance on May 3, 2024 for a second cycle of negotiations, which may produce negotiated prices effective from 2027, and Medicare states that more brand-name drugs are added to the negotiations every year.
That last point matters for a reader whose drug is not on today's list, and it is the subject of a later section.
How much will I save?
Nobody has published that number, and it is the question most people arrive with. What CMS published are national estimates for named years, and a national estimate is not a personal one. No official figure tells one person what this program does to their own pharmacy bill.
Here is what those estimates actually say.
| What CMS published | The figure | What it is not |
|---|---|---|
| Estimated saving if the negotiated prices had applied in 2023 | About 6 billion dollars in 2023 net covered prescription drug costs | Not money returned to anyone; a modelled comparison against a past year |
| Estimated saving for people with drug coverage in 2026 | About 1.5 billion dollars in 2026 | A total across everyone, not an amount for one person |
| What those drugs cost the program | About 56.2 billion dollars in 2023 | A measure of scale, not of your bill |
| What people paid out of pocket on them | About 3.9 billion dollars in 2023 | Again a national total, not yours |
A negotiated price is a ceiling on a list price, not a discount on your bill. That is our reading rather than a rule anyone states, and three published facts produce it.
The negotiated price is what the law calls a Maximum Fair Price and it attaches to the drug. CMS's published savings are estimates at national scale. And what you personally pay is set by your plan's own cost sharing and by which stage of the year you are in.
So the program moves a price, and your plan still decides your share of it. Those three facts are the government's. Putting them together is ours.
CMS's own instruction, on its own page, is to contact your plan for details on how these negotiated prices affect you. That is not a brush off. It is an admission that the plan holds the only version of the answer that applies to one person.
What if my drug is not on the list?
Most people are in this position, and the useful thing is that the list is a starting point rather than a fixed set. Medicare states that more brand-name drugs are added every year, and CMS published draft guidance for a second cycle that may produce prices from 2027.
The selection rules also tell you something about whether your drug is a candidate. The program aims at high expenditure, single source drugs with no generic or biosimilar competition.
A drug that already has a generic or a biosimilar version is therefore unlikely to be selected, for the straightforward reason that competition is already available to it.
Meanwhile the cost protections that apply to everyone do not depend on this program at all. Your plan's deductible cannot exceed 615 dollars in 2026, and your out of pocket spending on covered Part D drugs is capped at 2,100 dollars in 2026.
Those two rules reach every person with Medicare drug coverage, whatever is on the negotiation list.
How does this interact with the cap?
They are separate machines pointed at the same problem, and only one of them applies to everyone. The negotiation program changes what one drug costs. The out of pocket cap changes what you can be asked to spend across a whole year, whichever drugs you take and whichever plan you hold.
CMS treats the two as additive rather than as alternatives. CMS describes the negotiation savings as being in addition to other savings in the same law, including the first ever cap on out of pocket drug costs.
In practice the cap is the one a reader can plan around. It is 2,100 dollars in 2026 for out of pocket spending on covered Part D drugs, after which catastrophic coverage begins.
A lower price on a negotiated drug means your spending accumulates toward that ceiling more slowly, because the amount your cost sharing is calculated on is smaller.
Which is a real effect and an unquantifiable one from where a reader sits, because it depends on their plan and their prescriptions. This publication's article on the Part D out of pocket cap sets out how the ceiling is reached.
What changed this year
This is the year the program starts producing prices a reader can actually be charged, which makes 2026 the first year it shows up in anybody's real costs rather than in guidance about the future. Before this year it was a process. From January it is a price.
The negotiated prices for the first ten Part D drugs take effect on January 1, 2026. Before that date the program existed as a process; from that date it exists as a price.
The out of pocket ceiling underneath it also moved, to 2,100 dollars in 2026 from 2,000 dollars in 2025, and the deductible ceiling is 615 dollars in 2026.
Ahead of this year, CMS estimated that people with Medicare drug coverage would save about 1.5 billion dollars in 2026 under the projected standard benefit design. That is a national projection made before the year began, not a measured result.
Source: the CMS fact sheet on negotiated prices for 2026 and Medicare's drug coverage costs page.
What this means for you
Ten Part D drugs have negotiated prices and those prices start on January 1, 2026. CMS publishes the list and the prices in its own fact sheet, and this article points you at that document rather than retyping it, because a list copied second hand is not something you should have to trust.
What nobody publishes is what it does to your bill. The figures CMS released are national estimates for named years, and none of them can be divided down into a personal saving.
The reason is not evasiveness. The program sets a price, and your plan sets your share of that price, so the answer lives with your plan. CMS says so itself.
If your drug is not on the list, more are added every year, and a second round may produce prices from 2027. The rules that already protect you do not wait for that: a deductible that cannot exceed 615 dollars in 2026 and a ceiling of 2,100 dollars in 2026 on your out of pocket drug spending.
For how that ceiling works, read this publication's article on the Part D out of pocket cap. For spreading what you owe across the months, read the article on the Medicare Prescription Payment Plan.
FAQ
Where can I see the actual list of negotiated drugs and prices?
CMS publishes it in its fact sheet on negotiated prices for the Medicare Drug Price Negotiation Program, which is linked in the sources for this article. This publication points you there rather than reproducing the list.
The reason is a rule it applies to itself. A list of drug names and prices copied from a summary rather than read at the source is a second hand specific, and on a page about what medicines cost you that is not good enough.
What can be said from the source is that ten Part D drugs were selected for the first cycle and that they treat conditions including cardiovascular disease, diabetes, autoimmune diseases and cancer.
Why were these particular drugs chosen?
The law aims the program at high expenditure, single source drugs that have no generic or biosimilar competition. Each of those three conditions is doing work. High expenditure means Medicare already spends a great deal on the drug.
Single source means one company makes it. No generic or biosimilar competition means there is no cheaper equivalent already pushing the price down.
Together they describe drugs where the ordinary market pressure that lowers prices is absent, which is why negotiation was given a role there rather than across the whole formulary. CMS states that more brand-name drugs are added to the negotiations every year.
Will the negotiated price stay the same in future years?
No. CMS states that for each year after the first, it publishes an updated negotiated price for each selected drug, equal to the price published for the previous year increased by the annual percentage rise in the Consumer Price Index for all urban consumers. The price can also change if CMS and the manufacturer renegotiate it.
So a negotiated price is a level that moves with a published inflation measure rather than a fixed figure locked in place. This also means the figures published for 2026 are specific to 2026, and a reader looking at this page in a later year should check the current published price rather than assume the 2026 one still applies.
How much will this save me personally?
No published figure answers that, and this article will not manufacture one. CMS released national estimates. It estimated that if the negotiated prices had been in effect during 2023, they would have saved about 6 billion dollars in net covered prescription drug costs that year.
It also estimated that people with Medicare drug coverage would save about 1.5 billion dollars in 2026 under the projected standard benefit design. Both are totals across everyone, and both are estimates rather than measured outcomes.
What you pay depends on your own plan's cost sharing and on where you are in your plan year, which is why CMS's own instruction is to contact your plan for details.
Does a negotiated price mean my copayment drops?
Not automatically, and this is the distinction the whole article turns on. The negotiated price, which the law calls a Maximum Fair Price, attaches to the drug. What you hand over at the pharmacy is your plan's cost sharing, which the plan sets, applied at whichever stage of the plan year you are currently in.
A lower price on the drug generally means the amount your share is calculated from is smaller, and it means your spending accumulates toward the yearly ceiling more slowly. But the size of that effect is not published because it is not the same for two people in different plans.
What if I take a drug that is not on the list?
That is the position most people are in, and the protections that apply to everyone are unaffected by it. Your plan's deductible cannot be more than 615 dollars in 2026.
Your out of pocket spending on covered Part D drugs is capped at 2,100 dollars in 2026. After that, catastrophic coverage begins and covered Part D drugs cost you nothing out of pocket for the rest of that calendar year.
Neither of those depends on the negotiation program. Separately, Medicare states that more brand-name drugs are added to the negotiations every year, and CMS published draft guidance on May 3, 2024 for a second cycle that may produce prices effective from 2027.
